Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13. The company is preparing to release key late ...
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron ...
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
There is only one GLP-1 pill on the market, and it's not as effective as Ozempic for weight loss.Grace Cary/Getty Images Eli Lilly competitor Novo Nordisk kicked off the weight-loss drug craze ...